Latest / This Week In Medicine
NEJM February 2026 Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
This clinical study evaluates a promising medical advancement for patients with HER2-positive breast cancer who still have signs of the disease following their initial surgery and treatment. Researchers compared the effectiveness of a newer drug, T-DXd, against the long-standing standard of care, T-DM1, to see which better prevented the cancer from returning. The results were striking, showing that patients receiving T-DXd had a significantly higher survival rate without the disease recurring compared to those on the traditional therapy. While the new treatment demonstrated superior…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.